STAAR Surgical Co logo

STAA

STAAR Surgical Co

$59.13

Earnings Summary

Revenue
$0.08Mn
Net Profits
$0.01Mn
Net Profit Margins
13.49%

Highlights

Revenue:

STAAR Surgical Co’s revenue fell -99.87% since last year same period to $0.08Mn in the Q4 2022. On a quarterly growth basis, STAAR Surgical Co has generated -99.91% fall in its revenue since last 3-months.

Net Profits:

STAAR Surgical Co’s net profit fell -99.83% since last year same period to $0.01Mn in the Q4 2022. On a quarterly growth basis, STAAR Surgical Co has generated -99.92% fall in its net profits since last 3-months.

Net Profit Margins:

STAAR Surgical Co’s net profit margin jumped 30.8% since last year same period to 13.49% in the Q4 2022. On a quarterly growth basis, STAAR Surgical Co has generated -16.06% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the STAAR Surgical Co post its latest quarter earnings

EPS Estimate Current Quarter
0.19
EPS Estimate Current Year
0.19

Highlights

EPS Estimate Current Quarter:

STAAR Surgical Co’s earning per share (EPS) estimates for the current quarter stand at 0.19 - a -6.4% fall from last quarter’s estimates.

EPS Estimate Current Year:

STAAR Surgical Co’s earning per share (EPS) estimates for the current year stand at 0.19.

Key Ratios

Key ratios of the STAAR Surgical Co post its Q3 2022 earnings

Earning Per Share (EPS)
0.42
Return on Assets (ROA)
0.09
Return on Equity (ROE)
0.13

Highlights

Earning Per Share (EPS):

STAAR Surgical Co’s earning per share (EPS) jumped 55.56% since last year same period to 0.42 in the Q3 2022. This indicates that the STAAR Surgical Co has generated 55.56% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. STAAR Surgical Co’s return on assets (ROA) stands at 0.09.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. STAAR Surgical Co’s return on equity (ROE) stands at 0.13.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2019-10-30
0.05
0.05
0%
2019-02-21
0.02
0.07
250%
2019-10-30
0.09
0.12
33.33%
2019-05-01
0.05
0.09
80%

Company Information

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or 'ICL', which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

Organisation
STAAR Surgical Co
Headquarters
25651 Atlantic Ocean Drive, Lake Forest, CA, United States, 92630
Employees
692
Industry
Health Technology
CEO
Caren Mason

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*